The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 19, 2016
Filed:
Mar. 01, 2013
Applicants:
University of Cincinnati, Cincinnati, OH (US);
Cincinnati Children's Hospital Medical Center, Cincinnati, OH (US);
Inventors:
Edward J. Merino, Cincinnati, OH (US);
James C. Mulloy, Cincinnati, OH (US);
Guorui Li, Baltimore, MD (US);
Tiffany Bell-Horwath, Cheviot, OH (US);
Assignees:
Cincinnati Children's Hospital Medical Center, Cincinnati, OH (US);
University of Cincinnati, Cincinnati, OH (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07C 217/20 (2006.01); A61K 31/138 (2006.01); C07C 321/28 (2006.01); A61K 31/145 (2006.01); A61K 31/167 (2006.01); C07C 237/08 (2006.01); C07D 295/096 (2006.01); A61K 31/451 (2006.01); C07C 229/42 (2006.01); A61K 31/196 (2006.01); A61K 31/216 (2006.01); A61K 31/215 (2006.01); A61K 45/06 (2006.01); C07C 233/25 (2006.01); C07C 217/84 (2006.01); C07C 323/25 (2006.01); C07C 237/04 (2006.01);
U.S. Cl.
CPC ...
C07C 217/20 (2013.01); A61K 31/138 (2013.01); A61K 31/145 (2013.01); A61K 31/167 (2013.01); A61K 31/196 (2013.01); A61K 31/215 (2013.01); A61K 31/216 (2013.01); A61K 31/451 (2013.01); A61K 45/06 (2013.01); C07C 217/84 (2013.01); C07C 229/42 (2013.01); C07C 233/25 (2013.01); C07C 237/04 (2013.01); C07C 237/08 (2013.01); C07C 321/28 (2013.01); C07C 323/25 (2013.01); C07D 295/096 (2013.01);
Abstract
Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.